Mode
Text Size
Log in / Sign up
Phase 4 N=55 Treatment

The Jetstream G3™ Calcium Study

Peripheral Arterial Disease

Enrolled (actual)
55
Serious AEs
0.0%
Results posted
May 2015
Primary outcome: Primary: Luminal Area Change — 5.1; 8.3 mm^2 — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Jetstream Atherectomy System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Boston Scientific Corporation
Primary completion
Mar 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Luminal Area Change
5.1; 8.3 <0.0001 sig
SECONDARY
Adjunctive Therapy Use
62; 31; 8
SECONDARY
Residual Diameter Stenosis
-37

Summary

To investigate the treatment effects with the Jetstream G3 System in moderate to severely calcified peripheral artery disease in the common femoral, superficial femoral or popliteal arteries using intravascular ultrasound (IVUS).

Eligibility Criteria

Inclusion Criteria

  • The patient is ≥ 18 years of age.
  • Patient has claudication determined to be due to femoropopliteal lesion(s) requiring revascularization.
  • The target lesion(s) is/are located in the common femoral, superficial femoral or popliteal arteries.
  • The reference vessel lumen (proximal to target lesion) is ≥ 3.0mm.
  • The patient is an acceptable candidate for percutaneous intervention using the Jetstream G3 System in accordance with its labeled indications and instructions for use.
  • The patient has signed approved informed consent.
  • Moderate or severe vessel obstructive intraluminal calcification as demonstrated by IVUS and angiography.

Exclusion Criteria

  • Patient has an uncontrollable allergy to nitinol, stainless steel or other stent materials or to contrast agent.
  • Patient is unable to take appropriate anti-platelet therapy.
  • Patient has no distal runoff vessels.
  • Deep wall calcium.
  • Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.
  • Patient has target vessel with moderate or severe angulation (e.g., >30 degrees) or tortuosity at the treatment segment.
  • Patient has a history of coagulopathy or hypercoagulable bleeding disorder.
  • Patient is receiving hemodialysis or has impaired renal function (creatinine is > 2.5 mg/dl) at the time of treatment.
  • Patient has evidence of intracranial or gastrointestinal bleeding within the past 3 months.
  • Patient has had severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days.
  • Patient is pregnant or nursing a child.
  • Intended interventional treatment includes planned laser, brachytherapy or atherectomy procedure other than the Jetstream G3 System.

-

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01273623). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search